BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 29132566)

  • 1. Are There Alternative Strategies for the Local Management of Ductal Carcinoma in Situ?
    Rosso KJ; Weiss A; Thompson AM
    Surg Oncol Clin N Am; 2018 Jan; 27(1):69-80. PubMed ID: 29132566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ductal Carcinoma In Situ - Quo Vadis?
    Peltecu G
    Chirurgia (Bucur); 2021 Dec; 116(5 Suppl):S5-S6. PubMed ID: 34967322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feasibility of the Less Is More Approach in Treating Low-Risk Ductal Carcinoma In Situ Diagnosed on Core Needle Biopsy: Ten-Year Review of Ductal Carcinoma In Situ Upgraded to Invasion at Surgery.
    Podoll MB; Reisenbichler ES; Roland L; Bruner A; Mizuguchi S; Sanders MAG
    Arch Pathol Lab Med; 2018 Sep; 142(9):1120-1126. PubMed ID: 29582675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ductal carcinoma in situ: treatment or active surveillance?
    Kuerer HM
    Expert Rev Anticancer Ther; 2015; 15(7):777-85. PubMed ID: 25938920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS).
    Hwang ES; Hyslop T; Lynch T; Frank E; Pinto D; Basila D; Collyar D; Bennett A; Kaplan C; Rosenberg S; Thompson A; Weiss A; Partridge A
    BMJ Open; 2019 Mar; 9(3):e026797. PubMed ID: 30862637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of ductal carcinoma in situ on the outcome of invasive breast cancer. A prospective cohort study.
    Lopez Gordo S; Blanch Falp J; Lopez-Gordo E; Just Roig E; Encinas Mendez J; Seco Calvo J
    Int J Surg; 2019 Mar; 63():98-106. PubMed ID: 30738200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A retrospective alternative for active surveillance trials for ductal carcinoma in situ of the breast.
    Van Bockstal MR; Agahozo MC; Koppert LB; van Deurzen CHM
    Int J Cancer; 2020 Mar; 146(5):1189-1197. PubMed ID: 31018242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Finding the balance between over- and under-treatment of ductal carcinoma in situ (DCIS).
    Groen EJ; Elshof LE; Visser LL; Rutgers EJT; Winter-Warnars HAO; Lips EH; Wesseling J
    Breast; 2017 Feb; 31():274-283. PubMed ID: 27671693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Avoiding Overtreatment of Ductal Carcinoma in situ.
    van der Borden CL; Stoffers S; Lips EH; Wesseling J
    Trends Cancer; 2019 Jul; 5(7):391-393. PubMed ID: 31311652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology.
    Gradishar WJ; Anderson BO; Balassanian R; Blair SL; Burstein HJ; Cyr A; Elias AD; Farrar WB; Forero A; Giordano SH; Goetz MP; Goldstein LJ; Isakoff SJ; Lyons J; Marcom PK; Mayer IA; McCormick B; Moran MS; O'Regan RM; Patel SA; Pierce LJ; Reed EC; Salerno KE; Schwartzberg LS; Sitapati A; Smith KL; Smith ML; Soliman H; Somlo G; Telli ML; Ward JH; Kumar R; Shead DA
    J Natl Compr Canc Netw; 2018 Mar; 16(3):310-320. PubMed ID: 29523670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is there a low-grade precursor pathway in breast cancer?
    King TA; Sakr RA; Muhsen S; Andrade VP; Giri D; Van Zee KJ; Morrow M
    Ann Surg Oncol; 2012 Apr; 19(4):1115-21. PubMed ID: 21935747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ductal Carcinoma In Situ of Breast: From Molecular Etiology to Therapeutic Management.
    Hophan SL; Odnokoz O; Liu H; Luo Y; Khan S; Gradishar W; Zhou Z; Badve S; Torres MA; Wan Y
    Endocrinology; 2022 Apr; 163(4):. PubMed ID: 35245349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of subsequent invasive breast cancer after a diagnosis of ductal carcinoma in situ (DCIS).
    Cheung S; Booth ME; Kearins O; Dodwell D
    Breast; 2014 Dec; 23(6):807-11. PubMed ID: 25270228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ductal carcinoma in situ (DCIS). A highly treatable breast cancer.
    Mayo Clin Womens Healthsource; 2009 Oct; 13(10):1-2. PubMed ID: 19727033
    [No Abstract]   [Full Text] [Related]  

  • 15. Controversies in the Treatment of Ductal Carcinoma in Situ.
    Barrio AV; Van Zee KJ
    Annu Rev Med; 2017 Jan; 68():197-211. PubMed ID: 28099081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ductal carcinoma in situ (DCIS) of the breast: evolving perspectives.
    Sakorafas GH; Tsiotou AG
    Cancer Treat Rev; 2000 Apr; 26(2):103-25. PubMed ID: 10772968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tamoxifen added to radiotherapy and surgery for the treatment of ductal carcinoma in situ of the breast: a meta-analysis of 2 randomized trials.
    Petrelli F; Barni S
    Radiother Oncol; 2011 Aug; 100(2):195-9. PubMed ID: 21411161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal management of ductal carcinoma in situ of the breast.
    Sakorafas GH; Farley DR
    Surg Oncol; 2003 Dec; 12(4):221-40. PubMed ID: 14998563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multidisciplinary Shared Decision Making in the Management of Ductal Carcinoma In Situ of the Breast.
    Parikh P; Pockaj B; Wasif N; Halyard M; Wong W; Kosiorek HE; Dueck AC; Gray R
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3(0 3):S516-21. PubMed ID: 25986869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ASO Author Reflections: Active Surveillance for Ductal Carcinoma In Situ (DCIS).
    Oseni TO; Bahl M
    Ann Surg Oncol; 2020 Oct; 27(11):4466-4467. PubMed ID: 32440718
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.